CA2597265C - Anti-interferon alpha monoclonal antibodies and methods for use - Google Patents

Anti-interferon alpha monoclonal antibodies and methods for use Download PDF

Info

Publication number
CA2597265C
CA2597265C CA2597265A CA2597265A CA2597265C CA 2597265 C CA2597265 C CA 2597265C CA 2597265 A CA2597265 A CA 2597265A CA 2597265 A CA2597265 A CA 2597265A CA 2597265 C CA2597265 C CA 2597265C
Authority
CA
Canada
Prior art keywords
antibody
ifn
bioactivity
antibodies
ifna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2597265A
Other languages
English (en)
French (fr)
Other versions
CA2597265A1 (en
Inventor
Jacques F. Banchereau
Kiley Prilliman
Maria Virginia Pascual
Anna Karolina Palucka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor Research Institute
Original Assignee
Baylor Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Research Institute filed Critical Baylor Research Institute
Publication of CA2597265A1 publication Critical patent/CA2597265A1/en
Application granted granted Critical
Publication of CA2597265C publication Critical patent/CA2597265C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2597265A 2005-02-10 2006-02-09 Anti-interferon alpha monoclonal antibodies and methods for use Expired - Lifetime CA2597265C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65223305P 2005-02-10 2005-02-10
US60/652,233 2005-02-10
PCT/US2006/004643 WO2006086586A2 (en) 2005-02-10 2006-02-09 Anti-interferon alpha monoclonal antibodies and methods for use

Publications (2)

Publication Number Publication Date
CA2597265A1 CA2597265A1 (en) 2006-08-17
CA2597265C true CA2597265C (en) 2015-03-24

Family

ID=36694481

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2597265A Expired - Lifetime CA2597265C (en) 2005-02-10 2006-02-09 Anti-interferon alpha monoclonal antibodies and methods for use

Country Status (14)

Country Link
US (2) US8080638B2 (enExample)
EP (1) EP1851248B1 (enExample)
JP (2) JP5837730B2 (enExample)
KR (1) KR101363120B1 (enExample)
CN (1) CN101155831B (enExample)
AU (1) AU2006213800B2 (enExample)
BR (1) BRPI0607490A2 (enExample)
CA (1) CA2597265C (enExample)
IL (1) IL184808A0 (enExample)
MX (1) MX2007009466A (enExample)
NO (1) NO343054B1 (enExample)
RU (1) RU2431638C2 (enExample)
WO (1) WO2006086586A2 (enExample)
ZA (1) ZA200706425B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1796722A1 (en) * 2004-10-07 2007-06-20 Universität Zürich Type i interferon blocking agents for prevention and treatment of psoriasis
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
JP5837730B2 (ja) * 2005-02-10 2015-12-24 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗インターフェロンアルファモノクローナル抗体及び使用方法
JP5230022B2 (ja) * 2006-08-09 2013-07-10 ベイラー リサーチ インスティテュート 抗インターフェロンアルファモノクローナル抗体及び使用方法
JP2010512315A (ja) * 2006-12-06 2010-04-22 メディミューン，エルエルシー インターフェロンα誘導性薬力学的マーカー
EP2687232A1 (en) * 2006-12-06 2014-01-22 MedImmune, LLC Methods of treating systemic lupus erythematosus
EP2118324B1 (en) 2007-01-25 2012-06-13 Université Libre de Bruxelles Method for evaluating the response of an individual to a treatment with a type i interferon (ifn)
US20100209434A1 (en) * 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
CA2685147A1 (en) * 2007-05-03 2008-11-13 Medimmune, Llc Auto-antibody markers of autoimmune disease
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
WO2009108341A1 (en) 2008-02-28 2009-09-03 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
CN102083859B (zh) * 2008-05-07 2014-09-17 阿哥斯医疗公司 人源化抗人干扰素-α抗体
ES2978373T3 (es) 2008-08-14 2024-09-11 Genentech Inc Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas indígenas
CN101580546B (zh) * 2009-06-04 2011-09-14 中国疾病预防控制中心病毒病预防控制所 人源抗人干扰素α抗体及其应用
MX338932B (es) 2010-03-12 2016-05-06 Immunogen Inc Moleculas de union cd37 y sus inmunoconjugados.
CN105999293B (zh) 2011-04-01 2019-07-23 德彪发姆国际有限公司 Cd37结合分子及其免疫缀合物
JP6211513B2 (ja) * 2011-04-26 2017-10-11 ジェネンテック， インコーポレイテッド 自己免疫疾患の治療のための組成物及び方法
AU2013204880B2 (en) * 2011-04-26 2016-11-24 Genentech, Inc. Compositions and method for treating autoimmune diseases
US9902770B2 (en) 2013-03-15 2018-02-27 Janssen Biotech, Inc. Interferon alpha and omega antibody antagonists
US10112995B2 (en) * 2013-07-03 2018-10-30 Immunoqure Ag Human anti-IFN-α antibodies
WO2015095143A1 (en) * 2013-12-16 2015-06-25 The University Of North Carolina At Chapel Hill Depletion of plasmacytoid dendritic cells
EP3812398A3 (en) * 2015-01-23 2021-07-21 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
UA125496C2 (uk) 2015-06-08 2022-04-13 Дебіофарм Інтернаціонал, С.А. Спосіб лікування пацієнта з в-клітинним раком імунокон’югатом, який зв’язується з cd37 разом з антитілом, що зв'язується з cd20
AU2016316758B2 (en) 2015-08-28 2023-02-02 Debiopharm International, S.A. Antibodies and assays for detection of CD37
JP6979976B2 (ja) 2016-03-10 2021-12-15 ヴィエラ バイオ，インコーポレーテッド Ｉｌｔ７結合分子及びその使用方法
WO2018083633A1 (en) 2016-11-02 2018-05-11 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
CN107858449A (zh) * 2017-12-05 2018-03-30 安徽九川生物科技有限公司 一种犬干扰素α生物学活性检测方法
CN118638788A (zh) 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
RU2694672C1 (ru) * 2018-04-27 2019-07-16 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Вариабельные домены лёгкой и тяжёлой цепи мышиного моноклонального антитела против интерферона альфа (IFN-α) человека, антигенсвязывающий фрагмент (Fab) против IFN-α человека, содержащий указанные домены
CA3101790A1 (en) 2018-05-30 2019-12-05 Debiopharm International, S.A. Anti-cd37 immunoconjugate dosing regimens
WO2020202106A1 (en) 2019-04-04 2020-10-08 Janssen Biotech, Inc. Method of administration of an anti-ifn-alpha/-omega antibody
RU2737466C1 (ru) * 2019-12-30 2020-11-30 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Гуманизированное нейтрализующее антитело к интерферону-бета человека
RU2748953C1 (ru) * 2019-12-30 2021-06-02 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Рекомбинантный Fab-scFv на основе нейтрализующего антитела против интерферона бета-1а человека и антитела против рецептора ErbB2 человека
WO2021195469A1 (en) * 2020-03-27 2021-09-30 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
CN119841955A (zh) * 2023-12-19 2025-04-18 重庆艾生斯生物工程有限公司 一种抗MxA抗体或其功能性片段及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3001687C2 (de) 1980-01-18 1981-09-17 Kläger, Karlheinz, 8901 Neusäß Verstellbare Düse an einem handbetätigten Flüssigkeitszerstäuber
US4423147A (en) * 1980-04-11 1983-12-27 Secher David S Monoclonal antibody to interferon-α
US4362155A (en) * 1981-03-24 1982-12-07 Skurkovich Simon V Method and apparatus for the treatment of autoimmune and allergic diseases
US4605394A (en) * 1982-12-03 1986-08-12 Simon V. Skurkovich Methods for the treatment of pathological conditions by removing interferon from the organism
US4824432A (en) * 1981-03-24 1989-04-25 S.V.S. Laboratories, Inc. Method for treating AIDS and other immune deficiencies and immune disorders
DE3211263A1 (de) * 1981-03-31 1983-01-27 Otsuka Pharmaceutical Co. Ltd., Tokyo Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung
EP0139676B1 (en) * 1983-02-04 1992-11-25 Cytoclonal Pharmaceutics Inc. Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
FR2560212B1 (fr) * 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
AU2844889A (en) 1988-01-22 1989-07-27 Collagen Corporation Method for suppressing the growth of normal and cancer cells
US5889151A (en) * 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
AU653937B2 (en) * 1991-04-17 1994-10-20 Medisup International N.V. Water-soluble polypeptides having high affinity for interferons alpha and beta
JPH06510061A (ja) 1991-08-30 1994-11-10 ジェネンテク，インコーポレイテッド Ｉｄｄｍの治療法
RU2129437C1 (ru) * 1992-02-10 1999-04-27 Интерферон Сайнс Инк. Композиция альфа-интерферона и способ ее получения из лейкоцитов крови человека
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US5821078A (en) * 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5780027A (en) * 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6713609B1 (en) * 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
WO1998006431A2 (en) 1996-08-16 1998-02-19 Osther Kurt B Method for treating diabetes
US5804955A (en) * 1996-10-30 1998-09-08 Cherry Semiconductor Corporation Low voltage current limit circuit with temperature insensitive foldback network
US20030018174A1 (en) * 1997-10-06 2003-01-23 Genentech, Inc. Monoclonal antibodies to IFNAR2
EP1115737A4 (en) 1998-09-23 2004-11-24 Cleveland Clinic Foundation NEW GENES STIMULATED OR REPRESSED BY INTERFERON
AUPP670698A0 (en) 1998-10-23 1998-11-19 Monash University A method of regulation
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
JP5007007B2 (ja) 1999-11-15 2012-08-22 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 樹状細胞に特異的な抗原結合フラグメント、その組成物および使用方法、それによって認識される抗原およびそれによって得られる細胞
GB0001710D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
GB0001712D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
AU2001294577A1 (en) * 2000-09-21 2002-04-02 Schering Corporation Methods for preparing interferon producing dentitric cells
AU2002246955B2 (en) * 2001-01-09 2007-03-22 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FR2822845B1 (fr) * 2001-03-30 2003-12-12 Genodyssee Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
AU2003203079B8 (en) 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
AU2002368062A1 (en) * 2002-06-26 2004-01-19 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
EP1578397B1 (en) * 2002-11-15 2012-12-26 Genmab A/S Human monoclonal antibodies against cd25
EP1631590B1 (en) 2003-04-23 2011-07-27 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
ES2399050T3 (es) * 2003-12-10 2013-03-25 Medarex, Inc. Anticuerpos contra interferón alfa y sus usos
EP1796722A1 (en) * 2004-10-07 2007-06-20 Universität Zürich Type i interferon blocking agents for prevention and treatment of psoriasis
US7888481B2 (en) 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
JP5837730B2 (ja) 2005-02-10 2015-12-24 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗インターフェロンアルファモノクローナル抗体及び使用方法
JP5230022B2 (ja) 2006-08-09 2013-07-10 ベイラー リサーチ インスティテュート 抗インターフェロンアルファモノクローナル抗体及び使用方法
CN102083859B (zh) 2008-05-07 2014-09-17 阿哥斯医疗公司 人源化抗人干扰素-α抗体

Also Published As

Publication number Publication date
AU2006213800B2 (en) 2012-02-09
US20080160030A1 (en) 2008-07-03
CN101155831B (zh) 2015-08-19
EP1851248A2 (en) 2007-11-07
MX2007009466A (es) 2007-12-07
NO343054B1 (no) 2018-10-22
RU2007133608A (ru) 2009-03-20
KR101363120B1 (ko) 2014-02-13
BRPI0607490A2 (pt) 2009-09-08
US8333965B2 (en) 2012-12-18
CA2597265A1 (en) 2006-08-17
EP1851248B1 (en) 2016-08-10
IL184808A0 (en) 2007-12-03
RU2431638C2 (ru) 2011-10-20
WO2006086586A2 (en) 2006-08-17
JP5837730B2 (ja) 2015-12-24
JP2014111644A (ja) 2014-06-19
NO20074512L (no) 2007-10-31
US8080638B2 (en) 2011-12-20
KR20070107753A (ko) 2007-11-07
ZA200706425B (en) 2014-07-30
WO2006086586A3 (en) 2006-10-12
JP2008529529A (ja) 2008-08-07
AU2006213800A1 (en) 2006-08-17
US20120020963A1 (en) 2012-01-26
CN101155831A (zh) 2008-04-02

Similar Documents

Publication Publication Date Title
US8333965B2 (en) Anti-inteferon alpha monoclonal antibodies and methods for use
JP5230022B2 (ja) 抗インターフェロンアルファモノクローナル抗体及び使用方法
CA2865415C (en) Anti sez6 antibodies and methods of use
RU2542394C2 (ru) Гуманизированные антитела против light и их применение
ES2439490T3 (es) Anticuerpo anti-beta amiloide y usos del mismo
US11945861B2 (en) Human anti-IFN-α antibodies
TWI745670B (zh) 抗cd27抗體、其抗原結合片段及其醫藥用途
CA3050672A1 (en) Dll3-binding antibodies and drug conjugates thereof to treat cancer
KR20100097691A (ko) 인플루엔자의 치료 및 진단을 위한 조성물 및 방법
US9790271B2 (en) Methods for increasing immunoglobulin A levels
CN106573154B (zh) 中和抗乙型流感抗体及其用途
TW201902925A (zh) 抗cd40抗體、其抗原結合片段及其醫藥用途
US7888481B2 (en) Anti-interferon alpha monoclonal antibodies and methods for use
US20150166655A1 (en) Anti-interferon alpha monoclonal antibodies and methods of use
JP7811544B2 (ja) グリコシル化ｌａｇ３に対して特異的な抗体およびその使用方法

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250811

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106